Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-02-05
2011-12-27
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S303000, C540S575000, C544S362000, C546S119000
Reexamination Certificate
active
08084449
ABSTRACT:
The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof,pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.
REFERENCES:
patent: 3755340 (1973-08-01), Hoehn et al.
patent: 3833594 (1974-09-01), Hoehn et al.
patent: 3840546 (1974-10-01), Hoehn et al.
patent: 3856799 (1974-12-01), Hoehn et al.
patent: 3925388 (1975-12-01), Hoehn et al.
patent: 3966746 (1976-06-01), Hoehn et al.
patent: 3979399 (1976-09-01), Hoehn et al.
patent: 6825184 (2004-11-01), Cirillo et al.
patent: 2007/0167485 (2007-07-01), Coe et al.
patent: 2007/0254913 (2007-11-01), Dunn et al.
patent: 1003419 (1977-01-01), None
patent: 0076035 (1985-12-01), None
patent: 00/15222 (2000-03-01), None
patent: WO 02/060900 (2002-08-01), None
patent: 03/87064 (2003-10-01), None
patent: 2004/012684 (2004-02-01), None
patent: 2004/024728 (2004-03-01), None
patent: 2004/056823 (2004-07-01), None
patent: 2004/091482 (2004-10-01), None
patent: 2005/009362 (2005-02-01), None
patent: 2005/009439 (2005-02-01), None
patent: 2005/009440 (2005-02-01), None
patent: 2005/037224 (2005-04-01), None
patent: 2005/037280 (2005-04-01), None
patent: 2005/046586 (2005-05-01), None
patent: 2005/055940 (2005-06-01), None
patent: 2005/055941 (2005-06-01), None
patent: 2005/058892 (2005-06-01), None
patent: 2005/067537 (2005-07-01), None
patent: 2005/086873 (2005-09-01), None
patent: 2005/087236 (2005-09-01), None
patent: 2005/090348 (2005-09-01), None
patent: 2005/090352 (2005-09-01), None
patent: 2005/090353 (2005-09-01), None
patent: 2005/090354 (2005-09-01), None
patent: 02/081463 (2005-10-01), None
patent: 2005/094251 (2005-10-01), None
patent: 2005/094834 (2005-10-01), None
patent: 2005/094835 (2005-10-01), None
patent: 2005/099706 (2005-10-01), None
patent: 2005/104745 (2005-11-01), None
patent: 2005/112644 (2005-12-01), None
patent: 2005/118594 (2005-12-01), None
patent: 2006/005057 (2006-01-01), None
patent: 2006/017767 (2006-02-01), None
patent: 2006/017768 (2006-02-01), None
patent: 2006/050239 (2006-05-01), None
patent: 2006/055503 (2006-05-01), None
patent: 2006/055553 (2006-05-01), None
patent: 2006/062883 (2006-06-01), None
patent: 2006/062931 (2006-06-01), None
patent: 2006/065755 (2006-06-01), None
patent: 2006/065788 (2006-06-01), None
patent: 2007/016639 (2007-02-01), None
patent: 2007/016650 (2007-02-01), None
patent: 2007/018508 (2007-02-01), None
patent: 2007/018514 (2007-02-01), None
patent: 2007/022351 (2007-02-01), None
patent: WO 2008/009735 (2008-01-01), None
patent: 2005/095407 (2011-06-01), None
Naganuma et al. Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 3174-3176 (2009).
Peretto et al. Medicinal Research Reviews, vol. 29, pp. 867-902 (2009) (Abstract).
Laine Expert Review of Clinical Pharmacology,vol. 3, pp. 43-53 (2010) (Abstract).
Fryer and Jacoby, “Muscarinic Receptors and Control of Airway Smooth Muscle” Am J. Respir Crit Care Med; 1998; vol. 158 (5); pp. S154-S160).
Fryer, et al. “Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung” Life Sciences;1999; vol. 64(6-7); pp. 449-455 (Abstract provided) .
Pauwels, et al., “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” Am J. Respir Crit Care Med; 2001; vol. 163; pp. 1256-1276 .
Gwilt, et al., “The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation?” Pharmacology & Therapeutics; 2007; pp. 208-222.
Kummer and Lips, “Non-neuronal acetylcholine release and its contribution to COPD pathology” Drug Discovery Today: Disease Mechanisms; 2006; vol. 3; pp. 47-52.
Hohn, et al., “1H-Pyrazolo[3,4-b] pyridines” Journal of Heterocyclic Chemistry; 1972; vol. 9(2); pp. 235-253.
Patel and Malick, “Pharmacological Properties of Tracazolate: A New Non-Benzodiazepine Anxiolytic Agent” European Journal of Pharmacology; 1982; vol. 78; pp. 323-333.
Bare, et al., “Synthesis and Structure-Activity Relationships of a Series of Anxioselective Pyrazolopyridine Ester and Amide Anxiolytic Agents” J. Med. Chem; 1989; vol. 32; pp. 2561-2573.
Denzel, “Neue Synthese 1-unsubstituierter 1H-Pyrazolo [3,4-b] pyridin-5-carbon-saureeser” Archiv der Pharmazie; 1974; vol. 307(3); pp. 177-186.
Ochiai, et al., “New orally active PDE4 inhibitors with therapeutic potential” Bioorganic & Medicinal Chemistry; 2004; vol. 12; pp. 4089-4100.
Ochiai, et al., “Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors” Chem. Pharm. Bull.; 2004; vol. 52(9); pp. 1098-1104.
Shi, et al., “Pyrazolopyridines: Effect of Structural Alterations on Activity at Adenosine- and GABAa-Receptors” Drug Development Research; 1997; vol. 42; pp. 41-56.
Schenone, et al., “Synthesis and Biological Data of 4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylic Acid Ethyl Esters, a New Series of Al-Adenosine Receptor (A1AR) Ligands” Bioorganic & Medicinal Chemistry Letters; 2001; vol. 11; pp. 2529-2531.
Bondavalli, et al., “Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists” 2002; vol. 45; pp. 4875-4887.
De Mello, et al., “Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis” J. Med. Chem; 2004; vol. 47; pp. 5427-5432.
Provins, et al., “First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives” Bioorganic & Medicinal Chemistry Letters; 2006; vol. 16; pp. 1834-1839.
Provins, et al., “Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives” Bioorganic & Medicinal Chemistry Letters; 2007; vol. 17; pp. 3077-3080.
Ochiai, et al., “New orally active PDE4 inhibitors with therapeutic potential” Bioorganic & Medicinal Chemistry Letters; 2004; vol. 14; pp. 29-32.
Daly J. W. et al.; 1-methy1-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pp. 293-306; Birkhaeuser; Boston US.
Callahan James Francis
Lin Guoliang
Wan Zehong
Yan Hongxing
Bernhardt Emily
Glaxo Group Limited
Smith Robert J.
LandOfFree
Dual pharmacophores—PDE4-muscarinic antagonistics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dual pharmacophores—PDE4-muscarinic antagonistics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual pharmacophores—PDE4-muscarinic antagonistics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4316134